Value Health Voices

Encore: Why Medicare Advantage Premiums Can Be So Low, and Who Really Pays for It

From the archive: this episode first aired as Value Health Voices' debut, recorded in October 2024. Figures reflect that time. How can a Medicare Advantage plan charge seniors a $0 premium? Value Health Voices follows the money behind Medicare Advantage, from the federal payments insurers collect to the denials hospitals are pushing back on. In the show's first episode, re-released here, Dr. Anthony Paravati and Dr. Amar Rewari, both radiation oncologists and physician executives, walk through how Medicare Advantage works and why it has become the more popular choice for seniors in much of the country. They draw on their own work with commercial insurers, payment models and hospital contracting. They cover how plans keep costs down with narrow networks and utilization management; the three revenue streams that fund the extra benefits, from the benchmark-bid spread to risk adjustment and star-rating bonuses; and what that means in real dollars, with Medicare Advantage margins running about double those of commercial plans. They also weigh which seniors Medicare Advantage suits, and why the new prior authorization rule leaves claim denials and slow payment unresolved. Resources: KFF: Medicare Advantage enrollment update and key trends: https://www.kff.org/medicare/medicare-advantage-in-2026-enrollment-update-and-key-trends/ Medicare.gov: Compare Original Medicare and Medicare Advantage: https://www.medicare.gov/basics/get-started-with-medicare/get-more-coverage/your-coverage-options/compare-original-medicare-medicare-advantage CMS: Interoperability and Prior Authorization Final Rule: https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-and-prior-authorization-final-rule-cms-0057-f Connect with us: Website: https://www.valuehealthvoices.com/ YouTube: https://www.youtube.com/@ValueHealthVoicesPodcast Apple Podcasts: https://podcasts.apple.com/us/podcast/value-health-voices/id1777493904 Spotify: https://open.spotify.com/show/0cxnf4Il3QK3cvFFKxwPWL Instagram: https://www.instagram.com/valuehealthvoices LinkedIn: https://www.linkedin.com/company/value-health-voices/ X: https://x.com/ValHealthVoices TikTok: https://www.tiktok.com/@valuehealthvoices Newsletter: https://www.valuehealthvoices.com/newsletter

Paying More, Getting Less: Joel White's Five Fixes for America's Broken Health Care Market

American families now spend roughly one fifth of their income on health premiums, and if current trends hold, that number could reach 40 percent by 2032. In this episode of Value Health Voices, Dr. Amar Rewari and Dr. Anthony Paravati sit down with Joel White, president of the Council for Affordable Health Coverage and former staff director of the House Ways and Means Health Subcommittee, to understand why the system keeps charging more while delivering narrower networks, higher cost sharing, and more prior authorization friction. Joel argues that the United States does not have a free market in health care at all, but a system of localized monopolies shaped by regulation. He walks through how the medical loss ratio rule became a consolidation engine for vertically integrated insurers, how 340B drifted from a safety net program into what he calls a scam that never reaches the patient, and why pharmacy benefit managers capture roughly half of every dollar spent on drugs. Along the way, he explains what the PBM law signed earlier this year actually changes, why CMS is pushing site neutral payment into imaging, and why he believes fee-for-service medicine is a relic that should be retired. The conversation closes with Joel's five pillar agenda for affordability: real price and quality transparency, giving consumers the freedom to choose any approved plan, sending subsidies to people instead of insurers, driving down underlying medical costs through simpler value-based models, and restoring competitive markets through antitrust enforcement and more independent practice. Whether you lead a health system, run a practice, or simply pay a premium every month, this episode offers a clear map of the reforms that could reshape what care costs in the next few years. Resources: 【Council for Affordable Health Coverage Policy Priorities】 【Patients Deserve Price Tags Act (S.3548)】 【Association Health Plans Act (H.R. 2868)】 【LinkedIn】 【Instagram】 【TikTok】 【Newsletter】 【Apple Podcasts】 【Spotify】

Dr. Zeke Emanuel: The ACA's Fatal Flaw, Junking 340B, and Why AI Will Outperform Doctors

Dr. Ezekiel "Zeke" Emanuel helped design the Affordable Care Act, and 16 years later he has a surprising answer to what he would change: the law made an already impossible system even more complicated. In this episode of Value Health Voices, Drs. Anthony Paravati and Amar Rewari sit down with the oncologist, medical ethicist, and University of Pennsylvania professor for a wide-ranging conversation on what the ACA got right, what it got wrong, and why he believes the next wave of reform has to be built on three mantras: simplification, standardization, and digitization. From there the conversation runs through the greatest hits of health policy frustration. Zeke explains why the IRA drug negotiations were not the home run the country needed, how the biologic and small molecule patent protection timelines quietly bias the market toward more expensive drugs, and why he would scrap 340B entirely in favor of direct subsidies and a tax on manufacturers. The three physicians also dig into the RUC and physician fee schedule, radiation oncology's failed bundled payment experiment and the new ROCR proposal, percentage-based reimbursement for drugs that have driven up drug prices, and the growing evidence that private equity has yet to improve cost or quality anywhere in medicine. The episode closes with two of Zeke's most provocative arguments. Drawing on his new JAMA review of more than 100 studies, he makes the case that autonomous AI already matches or beats physicians in six core clinical areas, and that keeping a doctor in the loop will eventually degrade care rather than improve it. Then he turns personal, sharing which rule from his book Eat Your Ice Cream doctors most overlook and explaining why, more than a decade after writing "Why I Hope to Die at 75," his number has not moved. Resources: 【Dr. Ezekiel Emanuel Website】 【"Eat Your Ice Cream" By. Dr. Emanuel】 【LinkedIn】 【Instagram】 【TikTok】 【Newsletter】 【Apple Podcasts】 【Spotify】

Mark Cuban: Why You're Overpaying for Prescriptions – and Who's Pocketing the Difference

Mark Cuban did not set out to become the most disruptive force in American drug pricing. He just wanted to know why the same generic pill could cost $15 at one pharmacy and $500 at another. In this episode of Value Health Voices, Mark tells Dr. Anthony Paravati and Dr. Amar Rewari exactly what he found when he peered under the hood of the pharmacy supply chain, and why his answer was to launch Cost Plus Drugs with a radically simple promise: show patients the real cost, add a fair markup, and sell trust instead of marketing. The conversation goes deep into the machinery most patients never see. Mark breaks down how pharmacy benefit managers profit from rebates, spread pricing, and formulary threats, why brand manufacturers privately admit they cannot work with him, and how vertically integrated conglomerates shuffle billions between their own subsidiaries. He shares the story of a heart transplant patient whose life depended on a $200 generic her employer's plan refused to cover, and explains why he now spends his time telling CEOs to run their PBM contracts through AI and ask one question: where am I getting ripped off? Mark also lays out his blueprint for reform, including deductible credit for cash purchases, real consequences for repeat offenders, federally guaranteed healthcare loans, and full contract transparency. He makes the case for direct contracting between hospitals and self-insured employers, explains why he believes real change comes from outside Washington, and settles the question everyone keeps asking: whether he will run for president. This is a candid, unfiltered look at the business of American healthcare from the one outsider who decided to fix it himself. Episode Resources: Mark Cuban’s Cost Plus Drug Company Cost Plus Wellness for Self-Insured Employers JAMA Study on Potential Savings via Cost Plus Drugs

Ask Your Doctor: AMA CEO John Whyte on Deepfakes, Bots, and Who's Accountable When AI Gets It Wrong

A physician's mother called her, worried. She'd seen a video of her daughter selling a weight loss product. Her daughter had never made the video - a scammer had cloned her face. That's where we start with Dr. John Whyte, CEO of the American Medical Association, who calls deepfake doctors a rapidly developing public health crisis and has taken it on with an unlikely partner: SAG-AFTRA. As he tells it, members of Congress noticed that when the actors' guild and the physicians' lobby land on the same side, you're probably right. Underneath the fakes is the harder question - trust, and who has standing to give medical advice at all. Whyte's line: social media is the only place where you don't need a license to practice. We push him on where that line actually falls. In Utah, AI now renews prescriptions with no physician in the loop, and he doesn't hedge: the tech industry has become the tail wagging the dog, solving for problems nobody established were problems. But this isn't an anti-AI hour. He gets genuinely animated about what he wants built - an AI second opinion for every patient with a cancer diagnosis, closing the gap between rural and urban, community center and cancer center. Physician in the loop, patient in the loop. We also cover the money: budget neutrality, why physician payment still isn't tied to inflation, and whether real reform is close or this is just SGR with better manners. Plus the AMA's sharpened stance on private equity, and the prior auth bot wars - physicians using AI to appeal denials that insurers' AI wrote in the first place. Then we ask him the question worth asking: knowing all of it, would you do medicine again?

From Medicare to Maryland: Dr. Meena Seshamani on Making Healthcare Human Again

Transitioning from directing Medicare for 170 million Americans to managing a $20 billion state healthcare budget requires a unique blend of clinical, economic, and policy expertise. In this episode, Dr. Meena Seshamani, Secretary of the Maryland Department of Health and former Director of CMS, joins the show to break down the complex forces shaping state and federal healthcare finance. Listeners will gain an exclusive insider’s perspective on how aligning incentives and investing in population health can fundamentally transform patient care while driving sustainable systemic savings. Dr. Seshamani unpacks her pivotal role in launching the historic Medicare drug price negotiation program, revealing how utilizing real-world data and cross-industry collaboration led to billions in initial savings. The conversation also explores the strategic push to establish reimbursement structures for wraparound services - like community health workers and care navigators - to address the social determinants of health directly through the physician fee schedule. Furthermore, she details the evolution of Maryland's unique all-payer model and its current transition to the AHEAD model, prompting a critical question: could this localized approach to value-based care and global hospital budgets serve as the ultimate blueprint for the rest of the nation? If you want to stay ahead of the policies and payment models redefining the medical industry, hit subscribe and leave a review for Value Health Voices!

The Three Words AI Won't Say: Inside Mednet's Bet on Honest Medicine

Can AI replace physicians? Dr. Nadine Housri explains why Mednet merges AI in medicine with human expertise to solve the most complex patient cases. Episode Resources: Official Platform for Mednet Peter Densen Study on the Acceleration of Medical Knowledge JAMA Oncology Study on AI Accuracy vs. NCCN Guidelines Analysis of Evidence Levels within NCCN Guidelines Generative AI is rapidly entering healthcare, but even the most advanced models struggle to answer medicine's most nuanced, patient-specific questions. In this episode, Dr. Nadine Housri, co-founder of Mednet, joins Dr. Amar Rewari and Dr. Anthony Paravati to discuss how her platform bridges the gap between limited clinical guidelines and real-world patient care. You’ll discover how scaling expert wisdom not only solves impossible clinical cases but also prevents the dangerous de-skilling of modern physicians. Dr. Housri explains how Mednet evolved from a niche tool for oncologists into a nationwide digital hallway that allows clinicians to crowdsource expert clinical reasoning when traditional data falls short. The conversation tackles the vital difference between a confident AI hallucination and a human expert's willingness to admit "I don't know," exploring why large language models excel on board exams but often fail in complex clinical decision-making. The group also unpacks a growing debate surrounding ambient AI scribes and medical education: does automating documentation destroy a trainee's critical thinking, or does it pave the way for better adaptive problem-solving? Find out how hard-coding humility into artificial intelligence might be the key to upskilling the next generation of doctors. If you enjoyed this deep dive into the intersection of technology and clinical practice, please subscribe and leave us a five-star review!

The Value-Based Care Illusion: Consolidation and the Future of Specialist Medicine

Discover how health system consolidation impacts specialist stipends and care costs. Dr. Eric Bricker reveals how physicians can reclaim their market power. Episode Resources: AHealthcareZ DOJ Antitrust Lawsuits Against NY-Presbyterian and OhioHealth KFF Issue Brief on Provider Consolidation Overview of the No Surprises Act Dispute Resolution Process When it comes to negotiating healthcare payments, fairness is an illusion. It is entirely a game of market power. In this episode, Dr. Eric Bricker returns to unpack the massive impact of health system consolidation on specialist stipends, facility fees, and the everyday reality of patient care. You’ll walk away with a crystal-clear understanding of the hidden financial levers driving up healthcare costs and how recent Department of Justice lawsuits could disrupt the entire industry. Dr. Anthony Paravati and Dr. Amar Rewari join Dr. Bricker to examine the aggressive all-or-nothing contracting tactics that mega hospital systems use to monopolize markets and artificially inflate facility fees. The trio dissects the controversial world of specialist stipends, revealing how workarounds to the Stark Law and the influx of private equity are radically transforming physician compensation. They also debate whether the push for value-based care within Medicare Advantage is a genuine cost-control solution or just a cynical strategy by the government to shift the burden of rationing care to insurance carriers. You won't want to miss Dr. Bricker’s surprisingly radical framework for how doctors can collectively reclaim their agency and finally outmaneuver corporate administrators. If you want to stay ahead of the curve on the business of medicine, be sure to subscribe to the podcast and leave a review!

Do Hospitals "Launder" Billions in Medicaid Fraud? ft. Brian Blase

Discover how government policies distort U.S. healthcare. Brian Blase exposes Medicaid gimmicks, ACA exchange flaws, and healthcare policy reforms. Episode Resources: The Great Obamacare Enrollment Fraud Report Report on Medicaid Financing Reform and Provider Gimmicks U.S. healthcare spending accounts for nearly a fifth of our GDP, yet systemic failures and physician burnout continue to reach historic highs. In this episode of Value Health Voices, Dr. Amar Rewari and Dr. Anthony Paravati sit down with Brian Blase, President of the Paragon Health Institute, to unpack the massive legislative shifts inside the newly passed One Big Beautiful Bill Act. Clinicians and healthcare leaders will walk away with a clear understanding of how new federal policies are fundamentally altering healthcare economics, Medicaid funding, and everyday clinical practice. We explore the structural forces driving hospital consolidation, examining how government-subsidized demand and restricted supply have inadvertently inflated costs across the entire sector. Brian breaks down the controversial "legalized money laundering" of Medicaid provider taxes and reveals why enforcing site neutrality and Medicare payment reform could be the ultimate weapons against hospital monopolies. The conversation also tackles the heated debate over Medicaid work requirements, exposing staggering data on ACA exchange "phantom enrollees" that challenges the structural integrity of subsidized coverage. Will pushing for consumer-driven healthcare and expanding HSAs finally force high-priced providers to compete, or simply shift the burden to vulnerable patients? If you want to stay ahead of the curve on healthcare policy and economics, be sure to subscribe to Value Health Voices and leave us a review.

The Truth Behind Health Insurance Denials with Warris Bokhari

Claimable founder Warris Bokhari exposes the truth behind medical insurance denials. Learn how to successfully appeal claims and win life-saving patient care. Episode Resources: Official Website for Claimable Marshall Allen’s Official Website and "Never Pay the First Bill" NBC News: How AI Helps Patients Fight Insurance Denials STAT News: Investigation into UnitedHealth’s "nH Predict" Algorithm When a health insurance company denies life-saving medical care, it isn’t just a bureaucratic hurdle—it’s a hidden public health crisis that costs lives. In this episode of Value Health Voices, Dr. Amar Rewari and Dr. Anthony Paravati sit down with Time 100 Health List honoree Warris Bokhari, founder of Claimable, to expose the shocking reality behind the nearly one billion medical denials issued every year. Listeners will learn exactly how to fight back against predatory insurance tactics and successfully overturn wrongful claim rejections, especially in high-stakes fields like oncology. Drawing from his insider experience at Anthem and Apple Health, Warris pulls back the curtain on how insurers use proprietary AI algorithms and fabricated terms like "medically unnecessary" to boost profits at the expense of patient care. The conversation explores the heavy toll of prior authorization and utilization management, the disturbing conflict between fiduciary responsibility and clinical ethics, and how Claimable operates as the "TurboTax for health insurance appeals" to wage asymmetric warfare against corporate giants. Warris also reveals a brilliant, legally-backed framework for using ERISA laws and employer liability to force insurers into approving delayed treatments, but you'll have to listen to find out the single most important step every patient must take within 48 hours of receiving a denial letter. Don't let a devastating insurance denial dictate your health journey. Hit play to arm yourself with these essential medical advocacy tools. Be sure to subscribe to Value Health Voices, leave us a review, and check the show notes for a direct link to Claimable and other critical resources mentioned in this episode.

The Real Crisis Destroying US Healthcare ft. Sachin Jain

Dr. Sachin Jain reveals why healthcare faces a leadership crisis, not a payment crisis. Learn how SCAN Health Plan is transforming Medicare Advantage. Episode Resources: Healthcare in Action Official Website Dr. Sachin Jain on The Ethical Erosion of American Healthcare Details on SCAN Health Plan’s $250 Million Legal Victory SCAN Affirm Member Guide for LGBTQ+ Seniors American healthcare doesn’t have a payment crisis; it has a profound leadership crisis. In this episode, Dr. Sachin Jain, President and CEO of SCAN Group, dismantles the broken culture of modern medicine and reveals how his non-profit Medicare Advantage organization is successfully flipping the script on senior care. Tune in to discover actionable strategies for aligning clinical integrity with financial sustainability, empowering you to drive meaningful change within your own health system. Dr. Jain takes us under the hood of SCAN’s explosive growth, explaining why delegating full financial risk to provider groups is the ultimate antidote to the toxic cycle of traditional utilization management. He introduces his fascinating framework of "soft UM," challenging the industry's obsession with superficial quality metrics and exposing the "ethical erosion" plaguing profit-driven hospital boards. From designing hyper-targeted health plans for diverse populations to navigating the controversial debate over health systems dropping Medicare Advantage contracts, this conversation pushes boundaries and redefines the social determinants of health. Can we rely on corporate giants to save value-based care, or does the true solution lie in the hands of courageous, disruptive physician leaders? If you’re ready to stop accepting the status quo and start leading with impact, hit subscribe and leave us a five-star review. Be sure to check the show notes for more information on SCAN Health Plan and additional resources on the future of healthcare innovation.

The $200 Billion Healthcare Cartel Destroying Your Doctor: The MultiPlan Lawsuit with Matt Lavin

What is the MultiPlan lawsuit? Attorney Matt Lavin exposes how commercial insurers allegedly use price fixing to underpay out-of-network healthcare claims. Episode Resources Free Case Evaluation Form for Interested Providers and Physicians to Connect with an Attorney Gilbert LLP MultiPlan CMS: No Surprises Act Department of Labor: ERISA UnitedHealthcare A single intermediary company touches an estimated 80% of all out-of-network medical claims in the United States, yet most doctors have never even heard of it. To help us understand the massive MultiPlan lawsuit, we sit down with Matt Lavin, a partner at Gilbert LLP and the lead antitrust attorney at the center of the battle. He breaks down how this obscure pricing system might be quietly draining hundreds of billions of dollars from American medicine. Throughout the episode, Lavin explains the exact mechanics of how commercial health insurance companies process out-of-network claims and why the system is drawing scrutiny from the Department of Justice. He reveals how proprietary algorithms are allegedly used to aggressively suppress healthcare reimbursement rates, creating massive fees for insurers while leaving providers struggling and patients stuck with the balance. We also unpack the hub-and-spoke cartel theory that forms the foundation of this case, detailing the real-world financial impact on rural hospitals and private practices. If you are an independent physician dealing with unpredictable revenue or a practice manager trying to make sense of mysteriously slashed payments, this episode is for you. You will walk away with a clear understanding of the hidden corporate forces driving down your revenue and practical advice on how to audit your past claims to protect your business. About Matt Lavin: Matt Lavin is a partner at Gilbert LLP’s Washington, D.C. office. He has successfully resolved countless reimbursement disputes with commercial payors such as Aetna, Anthem, AmeriHealth, Ambetter, Beacon, Centene, HealthNet, Humana, Cigna, UnitedHealthcare, HealthNet, Magellan, and many Blue Cross Blue Shield entities and Blue Card Network plans. Matt has experience with practically every aspect of the business of healthcare and revenue cycle management and has handled suits against “cost-containment” vendors, like MultiPlan, that egregiously underprice the value of out-of-network claims.

The Business of Diagnostics: Reimbursement, PAMA & Innovation with Quest CMO Dr. Yuri Fesko

Quest Diagnostics CMO Dr. Yuri Fesko joins Value Health Voices to decode the Clinical Laboratory Fee Schedule, the impact of PAMA and SALSA, and the future of precision medicine. Episode Resources: Learn more about Quest Diagnostics Explore Quest's Consumer-Initiated Testing How does a flawed government policy threaten the very foundation of modern medicine? Nearly every clinical decision, from a routine check-up to advanced cancer treatment, begins with data from a lab test. But the system that determines the value and payment for these critical services is under threat. In this episode, we explore the complex world of clinical laboratory services policy and payment with an unparalleled expert, Dr. Yuri Fesko, Chief Medical Officer of Quest Diagnostics. We uncover how a poorly designed law could cripple patient access to testing, especially in rural communities, and stifle the life-saving innovation happening in diagnostics. This deep-dive conversation with Dr. Yuri Fesko breaks down the most pressing issues facing clinical laboratories today. We start with the Clinical Laboratory Fee Schedule (CLFS) and the disastrous impact of the Protecting Access to Medicare Act (PAMA). Dr. Fesko explains how PAMA’s flawed data collection, which surveyed only the largest, most efficient labs, has led to proposed reimbursement cuts of up to 15% annually, threatening the viability of smaller hospital and independent labs across the country. We then discuss the bipartisan RESULTS Act, a proposed solution to create a more accurate and equitable system. The discussion also tackles the immense administrative burden of prior authorization for lab testing, a major friction point for clinicians that delays diagnoses and care. We explore how technology, like Quest’s adoption of the Epic EMR system, aims to streamline this broken process. A significant portion of our conversation focuses on the challenges surrounding reimbursement for advanced diagnostics. Dr. Fesko provides a fascinating look into cutting-edge innovations like Minimal Residual Disease (MRD) testing in oncology, a revolutionary tool that can detect trace amounts of cancer DNA in the blood to help guide treatment decisions and avoid unnecessary, toxic chemotherapy. We also navigate the intricate landscape of laboratory-developed tests (LDT) regulation, weighing the pros and cons of proposed FDA oversight versus the existing accreditation framework. Finally, we touch on patient-centric improvements like price transparency, the power of lab data in public health initiatives, and the critical importance of interoperability in ensuring patients own and control their health records. This episode is an essential guide to understanding the policy, payment, and innovation that will define the future of diagnostic medicine. About Our Guest: Dr. Yuri Fesko is the Chief Medical Officer of Quest Diagnostics. With a background in internal medicine, hematology, and oncology, Dr. Fesko leads Quest's medical groups, payer access and reimbursement strategies, and research activities. He brings a unique perspective from the front lines of both clinical practice and the leadership of one of the world's largest laboratory services companies, offering deep insights into the regulatory and financial pressures impacting patient care and diagnostic innovation. Timestamps: (00:00) Why Lab Testing is the Foundation of Medicine (05:43) The Clinical Laboratory Fee Schedule (CLFS) Explained (09:22) PAMA: A Flawed Law Threatening Lab Services (14:51) The RESULTS Act: A Bipartisan Fix for PAMA (18:24) The Burden of Prior Authorization for Lab Testing (26:07) Improving the Patient Experience with Price Transparency (30:56) Innovation: Reimbursement for Minimal Residual Disease (MRD) Testing (41:52) The Complex Regulation of Laboratory-Developed Tests (LDTs) (46:15) Big Data: How Lab Results Shape Public Health (55:49) Future Risks & Opportunities for Clinical Labs

The Clinical Case for Sunlight Therapy to Reduce Hospital Stays with Dr. Roger Seheult

Dr. Roger Seheult makes the clinical case for sunlight therapy. Discover the evidence for using infrared light to reduce hospital stays by 30% and cut costs. Episode Resources: Learn from Dr. Seheult on his YouTube Channel Explore MedCram's Health Optimization Courses (CME available) Watch the Guy Foundation's Autumn Series on Light & Health Read the Glen Jeffery study in Nature Scientific Reports Explore the Swedish study on sun exposure and all-cause mortality Could a simple, free resource dramatically reduce hospital stays and save the healthcare system billions? In this episode, we explore the powerful clinical case for sunlight therapy with one of the most respected medical educators online, Dr. Roger Seheult. He begins with the astonishing story of a 15-year-old boy given two days to live due to a flesh-eating fungal pneumonia, who made a miraculous recovery after one simple request: to go outside. This episode confronts the "magical thinking" skepticism head-on, presenting a data-driven argument that hospitals and policymakers can't afford to ignore. We're joined by Dr. Roger Seheult - a quadruple board-certified physician in pulmonary, critical care, and sleep medicine, and the founder of Medcram - to dissect the science behind sunlight and infrared light. Dr. Seheult breaks down the groundbreaking randomized controlled trials, including recent studies in Nature, that demonstrate the profound link between infrared light and mitochondrial function. Learn how specific wavelengths of light can pass through the human body, making our cellular batteries (mitochondria) more efficient, boosting ATP production, and impacting the root cause of many chronic diseases. This robust photobiomodulation evidence suggests we've overlooked a fundamental element of human health. The discussion pivots from cellular mechanics to systemic impact, focusing on the staggering potential for reducing hospital length of stay. Dr. Seheult cites multiple studies showing that patients exposed to more sunlight or targeted infrared light are discharged 3-4 days earlier - a reduction of over 30%. We analyze the immense financial implications, calculating potential savings of $5,000-$7,500 per admission for hospitals operating on bundled DRG payments. The episode tackles the practical and bureaucratic hurdles, from the inertia of hospital administration to the need for a new light therapy reimbursement policy. We explore actionable pathways for change, including updates to CPT codes, integration into CMMI value-based care models, and the power of the HCAHPS patient satisfaction survey to drive adoption. This conversation makes a compelling case that adopting light therapy isn't just good medicine; it's a financial and ethical imperative. About Our Guest: Dr. Roger Seheult is a quadruple board-certified physician (Internal Medicine, Pulmonary Diseases, Critical Care Medicine, and Sleep Medicine) and an Associate Clinical Professor at the UC Riverside School of Medicine and on faculty at Loma Linda University. As a critical care doctor, he sees the sickest patients in the hospital, which pushed him to explore foundational health principles that could pull patients back from the brink. He is the co-founder of MedCram, a leading online medical education platform with millions of viewers, where he excels at explaining complex medical topics in a clear and accessible way. Timestamps: (00:00) A Miraculous Recovery: The Case of the Boy with a Flesh-Eating Fungus (02:49) The Science and Finance of Light Therapy (03:55) Deep Dive: A 15-Year-Old's Fight Against Fungal Pneumonia (11:10) The Clinical Case for Light Therapy: Examining the Evidence (15:22) How Infrared Light Boosts Mitochondrial Function (19:51) Sunlight Exposure, All-Cause Mortality, and Global Health Patterns (26:40) The Financial Impact: Reducing Hospital Length of Stay by 30% (31:28) Practical Implementation: How to Prescribe Light Therapy in a Hospital (34:40) Overcoming Barriers: The Financial and Logistical Case for Change (44:14) Pathways to Reimbursement: New Policy and Payment Models (47:35) Rediscovering Old Wisdom: The History of Heliotherapy (56:21) Actionable Resources & How to Get Involved

Physician Advocacy in California: How the CMA Fights Back with Dr. Shannon Udovic-Constant

Learn how physician advocacy in California is tackling the industry's biggest threats. Discover how the CMA fights Medi-Cal cuts, private equity, and physician burnout. Episode Resources: Learn about the California Medical Association (CMA) Explore the AMA's Resources on the Corporate Practice of Medicine Access the CMA's Model Medical Staff Bylaws AMA Venture capital and private equity investment snapshot AMA Legislative approaches to curb corporate influence in health care Read about SB 306 (Prior Authorization Reform) Follow Dr. Shannon Udovic-Constant on LinkedIn In this pivotal episode of Value Health Voices, we explore how physician advocacy in California is at the forefront of a nationwide battle for the soul of healthcare. California’s health system is facing its biggest stress test in a generation, with looming federal budget cuts under HR1 threatening to pull tens of billions from Medi-Cal, the state's healthcare backbone for 1 in 3 residents. How can doctors protect patient care and their own professional autonomy when faced with unprecedented financial and corporate pressures? Our guest, Dr. Shannon Udovic-Constant, immediate past president of the California Medical Association (CMA), provides a masterclass in turning crisis into opportunity. She reveals the strategies the CMA is deploying to defend the future of medicine, offering actionable insights for physicians everywhere who feel powerless against a broken system. This is a must-watch for any healthcare professional wondering how to reclaim their voice and drive meaningful change. This episode unpacks the core challenges and solutions shaping modern medicine. We dive deep into the devastating Medi-Cal cuts and HR1 impact, which could strip coverage from millions and close rural hospitals. Dr. Udovic-Constant explains how the CMA successfully passed a provider tax initiative (Proposition 35) to boost reimbursement rates, a critical victory now grandfathered in despite federal changes. This proactive approach to physician advocacy in California serves as a model for other states. We also confront the alarming rise of private equity in healthcare and its corrosive effect on physician autonomy. Dr. Udovic-Constant explains the importance of the corporate practice of medicine doctrine, a legal shield designed to prevent corporate interests from interfering with clinical decisions. She provides practical steps physicians can take, from structuring better contracts to utilizing the CMA's model staff bylaws, to protect the physician-patient relationship from profit-driven motives. We connect this corporate pressure directly to the epidemic of physician burnout and collective action, reframing burnout not as a personal failing, but as a symptom of a system that needs fixing. Dr. Udovic-Constant argues that proactive, aspirational engagement in organized medicine is the most potent antidote. Finally, we celebrate tangible legislative wins that demonstrate the power of organized medicine. Learn about the landmark California prior authorization reform bill (SB 306), which aims to cut administrative red tape by eliminating prior authorizations for services that are almost always approved. We also discuss new guardrails for AI in healthcare (AB 489), ensuring transparency when patients interact with chatbots instead of clinicians. Through these examples, this episode highlights a clear path forward, showcasing why effective physician advocacy in California is not just about defense—it’s about building a better, more sustainable, and physician-led future for healthcare. About Our Guest: Dr. Shannon Udovic-Constant is a board-certified pediatrician in San Francisco and the 156th Immediate Past President of the California Medical Association (CMA), the largest state medical association in the country. A passionate advocate for children's health, equity in care, and physician leadership, she has been instrumental in shaping policies to protect patients and empower doctors across California. (Timestamps / Chapters): (00:00) Intro: California's Healthcare System Faces a Generational Crisis (04:19) The CMA: A Bridge Between the Bedside and the Legislature (07:32) A State-Level Victory: Boosting Medi-Cal Reimbursement Rates (12:54) Defending Physician Autonomy Against the Corporate Practice of Medicine (16:28) The Data Behind California’s Healthcare Pressures (21:06) How Physicians Can Regain Power Through Contracts and Bylaws (24:36) The Looming Threat: How HR1 Cuts Endanger Medi-Cal (30:40) Legislative Victories: Tackling Prior Authorization and AI Deception (38:05) Transforming Physician Burnout into Proactive Advocacy (43:55) Final Thoughts: The Future of Healthcare is Physician-Led

AI in Oncology: The Reality & Future of Cancer Care with Dr. Sanjay Juneja

Is the rapid rise of artificial intelligence a threat to medicine or its greatest hope? In this episode, we tackle the massive hype and complex reality of AI in oncology with one of the leading voices in the field, Dr. Sanjay Juneja, also known as TheOncDoc. We break down what this technological revolution truly means for cancer patients, doctors, and the healthcare system at large. From uncovering hidden patterns in cancer data that defy human intuition to the practical challenges of implementation, we explore how AI is set to transform everything we thought we knew about medicine. Join us as we separate fact from fiction in the world of medical AI. Dr. Sanjay Juneja, a medical oncologist and VP of Clinical AI Operations at Tempest, shares his journey from social media educator to a trailblazer in health technology. We dive deep into how AI can address the "unwarranted variation in care" that leads to inconsistent patient outcomes across the country. Dr. Juneja explains how machine learning models can analyze vast datasets to find novel insights, much like Google's AlphaGo made a move in the game of Go that was inconceivable to human grandmasters. This episode explores the incredible potential of the future of AI in healthcare, from AI scribes developed to combat AI and physician burnout to new diagnostic tools that can predict hyperglycemic events from the sound of your voice or determine a tumor's molecular features from a simple pathology slide. However, the conversation doesn't shy away from the serious challenges ahead. We confront the "garbage in, garbage out" problem, discussing how biases in training data can lead to flawed or inequitable conclusions. A core part of our discussion focuses on the critical need for validating AI models in medicine before they are widely deployed, ensuring that these powerful tools are both safe and effective. We also explore the nuanced impact of AI and the doctor-patient relationship, debating whether an algorithm can truly be more empathetic than a human physician and what happens to trust when patients suspect their doctor's messages are AI-generated. Finally, we unpack one of the biggest hurdles to adoption: the issue of liability for AI in healthcare. When an AI model makes a mistake, who is responsible—the developer, the hospital, or the clinician who acts on its recommendation? This is a must-watch for any clinician, patient, or technologist seeking to understand the real-world implications of AI in oncology today and in the near future. About Our Guest: Dr. Sanjay Juneja (@TheOncDoc) is a triple board-certified medical oncologist who has become a leading global authority on the application of AI in medicine. He serves as the Vice President of Clinical AI Operations at Tempest, is a contributing writer for Forbes, and was credentialed by Harvard Medical School's inaugural "AI in Healthcare" executive program. Through his massive social media presence and podcast, Dr. Juneja has a unique talent for simplifying complex medical and technological topics for a broad audience. Timestamps / Chapters: (00:00) Introduction: Separating Hype from Reality in AI and Oncology (02:41) From Social Media Influencer to AI Trailblazer: Dr. Juneja's Journey (06:14) Tackling Unwarranted Variation in Cancer Care with AI (10:35) The Devil's Advocate: Bias, "Garbage In, Garbage Out," and AI's Flaws (19:10) Real vs. Hype: Current AI Applications Changing Medicine Now (24:22) Systemic Hurdles: Data Privacy, Reimbursement, and AI Adoption (33:30) Can an AI Be More Empathetic Than Your Doctor? (41:35) AI in the Clinic: Improving Workflow and Reducing Physician Burnout (47:15) Who's to Blame? Unpacking the Liability of AI in Healthcare (52:06) The 2-to-5-Year Future of AI in Oncology Episode Resources: Follow Dr. Sanjay Juneja on LinkedIn Follow Dr. Sanjay Juneja on Instagram Follow Dr. Sanjay Juneja on TikTok Follow Dr. Sanjay Juneja on YouTube Check out Dr. Juneja's Podcast

Decoding US Healthcare Policy Challenges Amid a Shutdown

From a government shutdown halting FDA approvals to the looming expiration of ACA subsidies threatening to raise insurance premiums for millions, the American healthcare system is facing a perfect storm. These mounting US healthcare policy challenges are creating unprecedented uncertainty for patients, providers, and innovators alike. In this episode, we're joined by healthcare regulation and policy expert Matt Wetzel, a partner at Goodwin Procter LLP, to dissect the interconnected crises plaguing Washington, D.C. and what they mean for the future of your healthcare. We connect the dots between the federal shutdown, expiring ACA enhanced premium tax credits, clandestine pharmacy benefit manager (PBM) practices, and Medicare's latest payment cuts. Why can't Washington compromise, and who is feeling the most pain? We explore the real-world consequences, including delays for companies seeking approvals for new drugs and devices, the degradation of hospital payer mix due to rising uninsured rates, and the political maneuvering that leaves everyday Americans caught in the middle. This discussion on US healthcare policy challenges uncovers the systemic dysfunctions, from legislative gridlock to the "wrecking ball" approach to policymaking that prioritizes disruption over stability. This episode provides a comprehensive breakdown of the most pressing issues in healthcare today. We uncover the truth behind Pharmacy Benefits Managers (PBMs) and the bipartisan push for PBM reform, exposing their fundamental conflicts of interest, the dirty tricks of "spread pricing" on generic drugs, and why their business model drives up costs for everyone. We also analyze the controversial Medicare efficiency adjustment included in the latest Medicare Physician Fee Schedule—a "lazy" blanket cut that penalizes specialists and creates further uncertainty in the medical technology market. If you want to understand the forces driving up your insurance costs and creating chaos in the US healthcare system, this is a must-watch conversation that unpacks the complex US healthcare policy challenges we all face. About Our Guest: Matt Wetzel is an attorney and Partner at Goodwin Procter LLP, based in Washington D.C. He is a leading expert in medical device and healthcare regulation, working with numerous biotech, medtech, and digital technology companies. As a seasoned health policy commentator, Matt provides deep insights into the administrative and regulatory hurdles impacting the healthcare industry, from the FDA and CMS to the NIH. Timestamps: (00:00) Introduction: A System in Crisis (01:55) The Government Shutdown's Widespread Impact on Healthcare (05:05) How the Shutdown Halts FDA Approvals for New Drugs & Devices (09:25) The Crushing Weight of Uncertainty on the Healthcare Business Community (11:34) The Looming Expiration of ACA Enhanced Premium Tax Credits (14:28) Why Can't Congress Agree on Extending ACA Subsidies? (20:09) The Hidden Bureaucracy Driving Up Health Insurance Costs (26:15) Decoding PBM Reform: Conflicts of Interest and Hidden Costs (33:24) The PBM Conflict of Interest: Serving Two Masters (37:50) PBM Trick Explained: What is "Spread Pricing"? (41:00) The "Halloween Surprise": Unpacking the Medicare Efficiency Adjustment (49:09) What's Next? Biotech, National Security, and Future Healthcare Legislation Learn More From Our Guest / Episode Resources: Learn more about Matt Wetzel's work at Goodwin Procter LLP

PBMs: They Make More When You Spend More: Inside the PBM Business Model (VHV fundamentals episode)

One of America's largest pharmacy benefit managers (PBMs) just announced they'll stop taking rebates from drug manufacturers. The Senate's response? "Not impressed." Why? Because rebates are just one of five profit driving "tricks" PBMs use to quietly inflate your drug costs. In this episode, Dr. Anthony Paravati breaks down the real money flow behind prescription drug pricing, how a system designed to reduce costs does the exact opposite You'll learn: The 7-player money map that explains where every healthcare dollar really goes The 5 PBM "tricks" that turn generics into goldmines How "spread pricing" means employers (and ultimately you) pay huge markups on actual drug cost Why regulatory capture keeps this system legal And why this reform moment in Washington matters right now If you're an employer, benefits consultant, or policymaker, this episode will change how you see pharmacy costs forever. If you're a patient, you'll finally understand why your prescriptions keep getting more expensive. Because every dollar diverted to middlemen is a dollar not going to care, wages, or innovation. 🎧 Listen now to understand the role PBMs have played to drive annual healthcare spend in the US to a ridiculous $4 trillion.

• Transcript

Ep. 21 340B Drug Pricing Program: Controversy & Reform

The 340B drug pricing program was created to help safety-net hospitals and clinics stretch their resources to care for low-income and uninsured patients. But has it spiraled out of control? Originally a modest plan, the program has exploded into a $130 billion market, leading to a fierce debate over who truly benefits from the massive discounts. Is it the patients, as intended, or are for-profit corporations, PBMs, and large hospital systems capturing the profits? In this episode, we unpack the controversy and explore the future of 340B. Joined by two of the nation's leading experts on the topic, we dissect the complex mechanics of the 340B drug pricing program and the powerful financial incentives that drive it. We explore how the program has grown exponentially, fueled by rising drug costs and the explosion of 340B contract pharmacies. This discussion sheds light on the central question: who benefits from the 340B program? Our guests break down how pharmacy benefit managers (PBMs) and major chains like CVS and Walgreens have become major players, diverting funds that were meant for patient care. We provide a clear, step-by-step example of how the money flows for a single prescription, revealing the winners and losers in this system. A significant focus of our conversation is on 340B in oncology, where high-cost drugs create enormous financial spreads for participating hospitals, often without any direct savings for the cancer patient. This raises critical questions about whether the program encourages the use of more expensive drugs and consolidates cancer care into large hospital systems. We also dive deep into the push for 340B program reform, covering the recent Senate hearings, the legal battles over state laws restricting manufacturers, and the debate over moving oversight from HRSA to CMS. We analyze proposals like a rebate model and increased transparency requirements to understand what the future may hold for this vital, yet deeply flawed, healthcare program. About Our Guests: Ted Okon: As the Executive Director of the Community Oncology Alliance (COA), Ted Okon is a nationally recognized voice on the policy and politics of cancer care. He is a frequent presence on Capitol Hill, advocating on critical issues like drug costs, Medicare reimbursement, and the changing economics of oncology. Amanda Smith: Amanda is Counsel at K&L Gates in their healthcare and FDA practice, with a specialized focus on the federal 340B drug pricing program. She advises clients on complex regulatory, legislative, and litigation matters related to the program and previously served as a healthcare law clerk for the U.S. Senate Committee on Finance. Timestamps / Chapters: (00:20) Understanding the 340B Drug Pricing Program (07:24) How the 340B Program Really Works (09:29) Who Truly Benefits from 340B Discounts? (12:03) The Financial Impact: How 340B Influences Drug Prices (16:33) Navigating the Regulatory Landscape: HRSA's Role and Limitations (22:03) The Rise of 340B Contract Pharmacies & PBM Influence (25:26) The Legal Battleground: State Laws and Lawsuits (30:21) FOLLOW THE MONEY: A $10,000 Drug Example (36:11) Hospital Eligibility and the Lack of Transparency (44:26) The Future of 340B Program Reform: Rebates, CMS Oversight & More (59:45) PREDICTIONS: What Will 340B Look Like in 2 Years? Learn More From Our Guests / Episode Resources: Learn more about the Community Oncology Alliance (COA) Learn more about K&L Gates' Healthcare Practice Subscribe to our channel Follow us on TikTok Follow us on LinkedIn

Ep. 20 Navigating Cancer Care in Uncertain Times with ACCC's Meagan O'Neill

How do we deliver high-quality cancer care in a system under pressure? Meagan O'Neill, Executive Director of the Association of Cancer Care Centers (ACCC), joins us to talk about workforce empowerment, technology as a multiplier, and building sustainable oncology systems for the future. Meagan shares her journey from oncology business consulting to national advocacy, shaped by her own personal experience with cancer care. With two-thirds of U.S. cancer programs in its network, ACCC plays a pivotal role in driving change across the oncology landscape. In this episode, we discuss: Why personal experience can reshape how we design cancer care Strategies to address workforce shortages through empowerment Using technology to amplify—not replace—clinical teams Building upstream cancer care capacity to improve community health Making value-based care real in oncology practices Interoperability and integrated models for better patient outcomes The role of diversity in improving adherence and patient engagement Key Takeaways Workforce empowerment is essential to meet rising patient needs. Technology should act as a force multiplier for clinicians. Patient-centered care must be prioritized at every level. Interoperability and upstream investment are critical for sustainable oncology systems. About the Guest Meagan O'Neill is the Executive Director of ACCC, which represents more than two-thirds of U.S. cancer programs. She previously worked in oncology business consulting and brings both professional and personal perspectives to driving systemic change in cancer care. Chapters 00:00 – Introduction to ACCC and Meagan O'Neill 04:58 – A Personal Cancer Journey 12:11 – Workforce Empowerment in Oncology 20:19 – Building Capacity in Cancer Care 25:25 – Patient-Centered Care 26:12 – Data-Driven Approaches 28:10 – Expanding Capacity with Nursing and APPs 30:37 – Leveraging Technology 34:36 – Navigating Claims and Denials 37:18 – Interoperability and Integrated Care 39:02 – Tailoring Oncology Models 43:09 – Telehealth and E-Consults 45:39 – Designing Future Oncology Care 51:35 – Reflections on ACCC's 50th Anniversary Keywords ACCC, cancer care, oncology, workforce empowerment, technology in healthcare, patient experience, healthcare systems, cancer treatment, healthcare innovation, patient-centered care, value-based care, interoperability, nursing, APPs, telehealth